Treatment of RCC cells with the synthetic integrin αVβ3 ligand RGD stimulated enhanced E-cadherin depletion, indicating synergistic cooperation between TGF-β1 and integrins. The gene discussed is TGFB1; the disease is renal cell carcinoma.